Libin to lead major international trial

The Federal and Provincial Governments, along with Medtronic and GE Healthcare, announced a $40M+ multi-partner funding agreement for REFINE ICD, a clinical trial to be led globally at the Libin Cardiovascular Institute of Alberta (LCIA) by Dr. Derek Exner. The trial, which will have 75 sites and screen 10K subjects across North America, Europe and Japan, seeks to assess a novel method devised by Dr. Exner to predict the likelihood of sudden cardiac arrest (the cause of up to 50K deaths in Canada and 3M-5M globally per year) in individuals who have already had a heart attack. Subjects fitting the criteria will be randomized for receiving an implantable cardioverter defibrillator (ICD) or for current treatment options.

Dr. D. Exner, with (seated r to l) Dr. E. Cannon, President, UCalgary, Hon. G. Weadick, Minister Alberta AET, Rob Anders, MP Calgary West, Michael Emery, Medtronic and Terri Lohnes, GE Healthcare (out of frame) looking on.

Dr. Exner, Professor of Cardiac Sciences at UCalgary, is currently the Medical Director of Cardiac Pacing and Electrophysiology at the Libin Cardiovascular Institute of Alberta. His work at the Institute builds on a 30+ year history of the LCIA being at the global forefront of cardiac electrophysiology research.

Government press releaseAlberta researchers get to the heart of cardiac research

Click the following images for a sample of TV, Radio and Print coverage of this story:

CBC Radio interview
Calgary Herald article
Global TV coverage
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s